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ABSTRACT 
Background: studies of IV magnesium sulphate as a treatment 
for acute asthma have had mixed results with some data suggesting 
a benefit for acute severe asthma, but not for mild to moderate 
asthma.  
Design: single-blind controlled clinical trial.  
Setting: Emergency Departments (ED) of two hospitals 
(ElShaab and Omdurman Teaching Hospitals). 
Patients: patients aged 18 to 60 years presenting with acute 
severe asthma and PEFR < 50% predicted on arrival to the ED.  
Intervention: All patients received nebulized salbutamol at 
regular intervals, and IV hydrocortisone. Two grams of IV 
magnesium sulphate were randomly administered to 25 patients 
(out of 50) using computer randomization program or nothing 30 
minute after ED arrival.  The primary efficacy end point was PEFR 
at 240 minute.  
Results: Fifty patients were included and mean PEFR at ED 
arrival was 33.7% predicted. At 240 min, patients receiving 
magnesium had a mean PEFR of 65.1% predicted compared to 
 V
48.2% predicted in those who did not received magnesium (CI 7.97 
and 25.89) with P. < 0.005.      
In conclusion this study indicated that when 2 g MgSO4 is 
given as an adjunct to standardized asthma therapy to patients 
presented with severe acute asthma, there is significant 
improvement in clinical scenario and pulmonary function. Thus 
these would support routine use of MGSO4 in patients with severe 
acute asthma.  
So the study recommended for further larger multicenter 
studies, should support or talk more about the effect of MgSO4 on 
moderate to severe Sudanese asthmatic patients.  
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INTRODUCTION AND LITERATURE REVIEW 
 
1.1. Definition of asthma: 
Asthma is a chronic, episodic, disease of the airways, and it 
is best viewed as syndrome. In 1997 the national Heart lung and 
blood institute (NHLBI) included the following features as integral 
to the definition of asthma; (1,2) recurrent episodes of respiratory 
symptoms; variable airflow obstruction that is often reversible, 
either spontaneously or with treatment; presence of airway 
hyperreactiviy and, importantly, chronic airway inflammation, 
which is characterised by oedema, infiltration with inflammatory 
cells  especially, mast  cells,  eosinophils,   T-lymphocytes, 
macrophages, neutrophils, and epithelial cells, hypertrophy of 
glands and smooth muscle and damaged epithelium. The 
inflammation results in the state of hyper-responsiveness where 
airways narrow easily in response to a wide range of stimuli.(3) 
This may result in coughing, wheezing chest tightness and 
shortness of breath, which are often worse at night. The airway 
narrowing is usually reversible but in some patients with chronic 
asthma the inflammation may lead to irreversible airways 
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obstruction.(4) In general the more severe the asthma the more 
frequent and severe are the attacks. 
All patients with asthma are at risk of having exacerbiations 
characterized by a progressive increase in shortness of breath, 
cough, wheezing or chest tightness, and by a decrease in 
expiratory airflow that can be quantified by simple measures of 
pulmonary function such as the peak expiratory flow rate (PEFR). 
Terms like acute asthma (AA)/ asthma attack, or status asthmatics 
have been used to describe this condition. The severity of 
exacerbations may range form mild to life threatening. 
Deterioration usually progress over hours, days, or "weeks; 
however, a few patients have sudden (over minutes) and 
unexpected increase in airway obstruction.(5) 
1.2. Prevalence and etiology: 
Asthma is very common; it is estimated that 4 to 5% of the 
population of the united State is affected. Similar figures have been 
reported from other countries. Bronchial asthma occurs at all ages 
but predominantly in early life. About one-half of cases develop 
asthma before age 10, and another third occur before age 40. In 
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childhood, there is a 2 : 1 male/female preponderance, but the sex 
ratio equalizes by age 30.(6) 
Acute asthma (A.A) is a common medical emergency faced 
by Emergency Department (ED) and intensive care specialists. In 
the United States, asthma represents the 11th most frequent ED 
diagnosis nationwide, and adolescents and young adults are the 
most likely age groups to visit the ED for treatment.(7)Women visit 
the ED and are hospitalized for AA twice as often as men.(8.9)  
Previous data suggested that 40% of these hospitalizations 
occur during the premenstrual phase of the cycle.(10) Men are less 
likely than women to report severe asthma symptoms and activity 
limitations in the presence of airway obstruction.(11) 
1.3. Pathophysiology: 
Different triggers cause asthma exacerbations by inducing 
airway inflammation or provoking acute bronchospasm or both. 
Triggers vary from person to person and from time to time. 
Exposure to indoor and outdoor allergens, air pollutants, 
respiratory tract infections (primarily viral), exercise, whether 
changes, foods, additives, drugs, and extreme emotional 
expressions are me main triggers identified clinically. Other factors 
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that may cause exacerbations are rhinitis, bacterial sinusitis, poly 
posts, menstruation, gastroesophageal reflux, and pregnancy. The 
mechanisms of acute airflow limitation vary according to the 
stimulus. Allergen-induced bronchoconstriction results from the 
IgE-dependent release from airway mast cells of mediators, 
including histamine, prostaglandins, and leukotrienes, that 
contract the smooth muscle.(12)Acute airflow limitation may also 
occur because airways in asthma are hyperresponsive to a wide 
variety of stimuli.   In   this   case,   the   mechanisms   for   causing 
bronchoconstriction consist in combinations of release of 
mediators from inflammatory cells and stimulation of local and 
central neural reflexes. Finally, airflow limitation results from 
edematous swelling of the airway wall with or without smooth-
muscle contraction. The increase in microvascular permeability 
and leakage leads to the mucosal thickening and swelling of the 
airway outside the smooth muscle. Progressive airway narrowing 
due to airway inflammation and/or increased bronchiolar smooth-
muscle tone is the hallmark of an asthma attack, and leads to 
increased flow resistance, pulmonary hyperinflation, and 
ventilation/perfusion (V/Q) mismatching. Without correction of 
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the airway obstruction, respiratory failure is a consequence of 
increased work of breathing, gas exchange inefficiency, and 
respiratory muscle exhaustion.(12) 
Gas Exchange: 
Mild-to-moderate hypoxemia, along with hypocapnia and 
respiratory alkalosis, are common arterial blood gas (ABG) 
findings in severe AA.(13,14) If airflow obstruction is severe and 
unrelieved, there may be progression to hypercapnia and 
metabolic acidosis, the former as a result of muscle fatigue and 
inability to maintain adequate alveolar ventilation, and the latter a 
result of lactate production by the respiratory muscles exceeding 
clearance mechanisms. 
Asthma Attack Evolution: 
There are two different pathogenic scenarios involved in 
the asthma attack progression.(15) When airway inflammation is 
predominant, patients show a progressive (over many 
hours/days, or even weeks) clinical and functional deterioration 
(type 1 or slow-onset acute asthma). Upper respiratory tract 
infections were frequent triggers, and these patients exhibited a 
slow therapeutic response. Also, they may have allergic 
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inflammation with eosinophils in the airways. In the less common 
asthma progression scenario, bronchospasm is predominant and 
patients presenting with a sudden-onset asthma attack (type 2 or 
asphyxic or hyperacute asthma) characterized by rapid 
development of airway obstruction (<3 to 6 h after the onset of the 
attack). Respiratory allergens, exercise, and psychosocial stress are 
the most frequent triggers. Surprisingly, these patients show a 
more rapid and complete response to treatment. Finally, they have 
a predominance of neutrophils in their airways.(16) 
Fatal asthma: 
In many countries, asthma mortality increased from the 
1960s to the second half of the 1980s, but reached a plateau and has 
subsequently declined.(17,18) This recent downward trend may 
reflect better management of this condition in primary care. 
Asthma has a, low mortality rate compared with other lung 
diseases, but mortality does occur, typically in patients with 
poorly controlled disease whose condition gradually deteriorates 
over a period of days or even weeks before the fatal attack.(19,20) 
Occurrence of this type of asthma progression is between 60% and 
90% of adults with AA who have fatal and near-fatal 
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crises.(19,20,21,22,23) This observation suggests many patients have a 
window of opportunity for recognition and reversal of this period 
of deterioration. Infrequently, death occurs suddenly. Accordingly, 
most deaths are preventable, and a useful practice is to assume 
that every exacerbation is potentially fatal.(23,24) 
The majority of deaths occur at home, work, or during 
transport to the hospital. The most specific marker associated with 
an increased risk of dying from asthma is a history of repeated 
hospital admissions, particularly if patients required ventilatory 
assistance.(25,26) Nevertheless, a history of recurrent admissions is 
found in only 36% of fatal cases and ventilatory assistance or 
admission to an ICU in only 6%.(27) Although the presence of such 
events is extremely important in a given patient, their absence is of 
no value in assessing risk.(23) It has been reported that a subgroup 
of patients with near-fatal asthma have blunted perception of 
dyspnoea, and show more ED visits, hospitalizations, near-fatal 
asthma attacks, and deaths.(28,29)Additional epidemiologic fatal-
asthma markers include psychiatric illness,(30) illicit drug use,(31,32) 
and the lack of an asthma self-management plan. Also, anxiety and 
depression are related to the outcome of ED treatment.(33) 
 8
Two hypotheses have been postulated for the cause of 
asthma-related deaths. Cardiac arrhythmias may contribute to 
some of the observed mortality, particularly in adults. The risk is 
theoretically increased by hypokalemia and prolongation of the 
QTc interval coupled to the use of [beta]-agonists in high 
doses.(34,35) However, in a series of patients with near-fatal attacks, 
few arrhythmias other than sinus tachycardias and bradycardias 
were found(19,36)While some have claimed that this mechanism of 
death is supported by literature that points to an association 
between more [beta]-agonist use and mortality, this association 
could be explained on the basis of more severe asthma requiring 
more treatment and exhibiting a higher death rate despite 
treatment, not because of it.(37) A more likely hypothesis is that 
deaths occur as a result of asphyxia due to severe limitation of 
airflow and hypoxemia. This hypothesis has received support 
from the pathologic evidence indicating that patients with fatal 
asthma almost invariably have extensive airway obstruction, with 
mucous plugging and dynamic hyperinflation apparent even at 
autopsy.(38) 
1.4. Emergency department management: 
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1.4.1. Assessment: 
AA is a medical emergency that must be diagnosed and 
treated urgently. The assessment of an asthma exacerbation 
constitutes a process with two different dimensions: (1) a static 
assessment to determine the severity of attack, and (2) a dynamic 
assessment to evaluate the response to treatment. Overall, it 
requires an analysis of several factors.(39,40) 
1.4.2. Medical History: 
A brief history pertinent to any exacerbation should be 
obtained. The objectives are to determine time of onset and 
severity of symptoms, especially compared with previous 
exacerbations, all current medications, prior hospitalizations and 
ED visits, prior episodes of respiratory failure (intubation, 
mechanical ventilation), and psychiatric or psychological disorder. 
The existence of such events has been. associated with poor 
outcomes, but their absence  does not ensure'low risk.(25,26,41) 
A number of conditions may mimic or complicate the 
diagnosis of AA. The absence of a history of asthma, particularly 
in an adult, should alert the ED physician to an alternative 
diagnosis.(40) Congestive heart failure, particularly predominant 
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left ventricular failure or mitral stenosis, occasionally may present 
with episodic shortness of breath accompanied by wheezing. 
Perhaps the most common and most difficult diagnostic problem 
in asthma is its differentiation from COPD. In subjects > 40 years 
of age, a distinction between COPD and asthma is often difficult, if 
not impossible. Laryngeal, tracheal, bronchial obstruction resulting 
from any of a number of causes may produce shortness of breath, 
localized wheezing, inspiratory strider localized over the trachea, 
or unilateral hyperinflation noted on chest radiography, which 
often mimics asthma. Recurrent small pulmonary emboli may be 
manifested by attacks of shortness of breath and, very rarely, 
wheezing heard oil careful auscultation. Finally, recurrent attacks 
of shortness of breath at rest may be due to the hyperventilation 
syndrome.(41)   
1.4.3. Physical examination: 
Particular attention should he paid to the patient's general 
appearance. Patients with the most severe conditions will he 
sitting upright.(42) The use of accessory muscles has received 
attention as an indicator of severe obstruction, and the presence of 
sternocleidomastoid   retractions   or   suprasternal   retraction 
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correlated with impairment in lung function.(43)In consequence, 
accessory muscle use can be considered a useful sign of severe 
airflow obstruction. 
Respiratory rate (RR) > 30 breaths/ min, tachycardia > 120 
beats/ min, or PP > 1.9 mm Hg have been described as vital signs 
of acute severe asthma. However, composite data from large 
clinical studies (44,45) demonstrated that > 50% of patients with 
acute severe asthma have heart rates ranging between 90 
beats/min and 120 beats/min, with only 15% exceeding this value. 
In general, successful treatment of airflow obstruction is associated 
with a decrease in heart rate/ although some improving patients 
remain tachycardia because of the chronotropic effects of 
bronchodilators. 
While distinguishing between asthma-related tachycardia 
and treatment-related tachycardia can be difficult, patients who 
note subjectively improved, breathing hut exhibit a fine tremor are 
likely receiving excessive [beta]-agonist dosing. Specifically older 
patients tend towards treatment-related tachycardia.(46) RRs range 
between 20 breaths/min and 30 breaths/min in > 50% of patients, 
and are [greater than or equal to] 30 breaths/min in < 20% of 
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patients. In severe airflow obstruction, Plusus Paradox's is greater 
titan the normal value of 10 mm Hg and typically > 15 mm Hg; 
however, only severe PP (> 25 mm Hg) was a reliable indicator of 
severe asthma.(47) Additionally, PP is not easy to evaluate. It is also 
extremely important to emphasize that PP is dependent on patient 
effort, since it reflects the inspiratory and expiratory excursions of 
thoracic pressure resulting from active respiratory muscle 
contraction. When patients fail to improve and have fatigue, with 
decreasing respiratory effort, PP will fall. Interpreting the falling 
PP in this context as improvement in airflow obstruction is a grave 
error. Finally, wheeze and dyspnea are present in virtually all 
patients with AA, and they correlated poorly with the degree of 
airflow limitation.(48) 
1.4.4. Objective Measurement of Airflow Obstruction: 
The measurement of lung function provides a more 
objective assessment of obstruction, but does depend on good 
technique and adequate patient effort. On presentation, after the 
initial treatment, and at subsequent frequent intervals, it 
constitutes an integral part of the assessment of disease severity 
(static assessment) and the response to therapy (dynamic 
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assessment) in any patient > 5 years of age.(1,2) Measurement of 
airflow obstruction should be made using one of following 
techniques: PEFR measured with a peak flowmeter, or FEV1 
determined by spirometry. Many studies (40,49) have found 
satisfactory correlations between both measures among healthy 
and stable patients or patients with acute asthma. PEFR values 
tended to have more variability when pulmonary function was 
more impaired, and to underestimate the degree of pulmonary 
impairment. Even though spirometry is the "gold standard" in 
most asthma patients, it is easier to measure PEFR than FEV1; 
PEFR measurement is common in the ED because it is inexpensive, 
portable, and safe. The typical asthmatic patient who presents for 
care to an ED will exhibit a broad range of PEFR and FEV1 
values.(46,50) Approximately 55% of patients will have values < 40% 
of normal, and one fifth will range between 40% and 60% of 
normal. 
1.4.5. Pulse Oximetry: 
Measurement of oxygen saturation by pulse oximetry (SOi 
is necessary in all patients with AA to exclude hypoxemia; it 
allows monitoring of SO2. on a continuous basis. The measure of 
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SO2 indicates which patients may be in respiratory failure and 
therefore in need of more intensive management.(51) The goal of 
treatment should be to maintain SO2 at [greater than or equal to] 
92%(52,53); however, it does not help to predict which patients can 
behospitalized.(54)  
1.4.6 Arterial blood gases (ABGs): 
ABG determination is rarely necessary before the initiation 
of treatment. Because of the accuracy and utility of pulse oximetry 
only patients whose oxygenation is not restored to > 90% with 
oxygen therapy require ABG determination. When adequate 
oxygenation remains a problem despite supplemental oxygen, 
additional complicating conditions such as pneumonia should be 
considered. Repeated ABG sampling usually is not needed to 
determine whether a patient is deteriorating or improving.(55) 
1.4.7 Chest Radiography: 
Chest radiography plays only a small role in the assessment 
and management of patients with acute asthma (AA) is indicated 
only in patients who present with signs or symptoms of 
pneumothorax  (pleuritic  chest pain,  mediastinal crunch, 
subcutaneous   emphysema,   cardiovascular   instability,   or 
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asymmetric breath sounds), in patients with clinical findings 
suggestive of pneumonia, or in an asthmatic patient who after 6 to 
12 h of intensive treatment does not respond to therapy. 
1.4.8. Cardiac Rhythm Monitoring: 
ECGs need not be routinely obtained, but continual 
monitoring is appropriate in older patients/56) and in those with 
coexisting heart disease.(2) 
1.4.9. Response to Therapy: 
Measurement of the change in PEFR or FEVi over time may 
be one of the best ways to assess patients with acute asthma and 
predict the need for hospital admission. The response to initial 
treatment in the ED is a better predictor of the need for 
hospitalization than is the severity of an exacerbation at 
presentation.(57) Early response to treatment (PEFR or FEV1) at 30 
min) is the most important predictor of outcome.(58) PEFR variation 
over baseline > 50 L/min and PEF            > 40% of normal, both 
measured at 30 min after beginning of treatment, are predictors of 
good outcome.(59,60) 
 
1.5. Treatment: 
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1.5.1. Convensional therapy: 
Initial ED treatment of patients with AA should be titrated 
to the severity of presentation and the response to initial 
treatment. Supplemental oxygen is recommended for the majority 
of patients. The goal of treatment should be to maintain SO2 at 
greater than or equal to 92%. Inhaled [beta]-agonists and 
corticosteroids are the core treatments for almost all patients. The 
addition of IB to [[beta]-agonists seems indicated as first-line 
therapy in adult patients with severe exacerbations; pMDIs with 
large-volume valved spacers are preferred to jet nebulizers, 
particularly in patients with the most severe obstruction. Inhaled 
corticosteroids could produce early therapeutic effects in patients 
with prolonged duration of symptoms before ED presentation. 
1.5.2. Magnesium: 
1.5.2.1. Introductions: 
Magnesium is the fourth most abundant mineral in the 
body and essential to good health approximately 50% of total body 
magnesium is found in bone. The other half is found 
predominantly inside of body tissues and organs. Only 1% of 
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magnesium is found in blood but the body work very hard to keep 
blood levels of magnesium constant.(61) 
Magnesium is needed for more than 300 biochmaical 
reactions in the body. It helps maintain normal muscle and nerve 
function, keeps heart rhythm steady, supports a healthy immune 
system, and keeps bones strong. Magnesium also helps regulate 
blood sugar levels, promotes normal blood pressure, and is known 
to be involved in energy metabolism and protein synthesis. (62,63) 
Dietary magnesium is absorbed in the small intestines and 
is excreted through the kidneys.(61,63,64) Green vegetable such as 
spinach are good sources of magnesium, beans, peas, nuts and 
seeds and whole, unrefined grains are also good sources of 
magnesium.(65) Refined grains are generally low in 
magnesium.(64,65) 
The daily recommended Mg requirement is 250 to 350 mg 
(10.4-14.6 mmol) in adults and an additional 100 to 150 mg in 
children and pregnant or nursing women.(66) 
 
 
1.5.2.2. Biological considerations: 
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Assay of total plasma Mg by spectrophotometry is precise 
and easy to perform (0.7-1.1 mmol L-1 or 1.4-2.2 mEq L-1, or 16.8-
26.4 mg L-l). However, owing to the intracellular nature of this ion, 
these values are not exactly indicative of the Mg pool in the 
organism or of a possible state of deficiency.(67) Other 
concentrations have been studied to allow better assessment of 
true Mg deficiencies, namely intracellular (8-10 mmol L-1)(68) and 
ionized plasma Mg (0.65 ± 0.1 mmol L-l) concentrations. 
Interferences with calcium ions at the level of the Mg 
electrode reduce the relevance of the ionized Mg assay.(67) Because 
of the long life of Mg and its slow turnover, erythrocytic Mg might 
be a better indicator of deficiency (values in the literature: 2.10 ± 
0.4 mmol-L-l)(65,69)  Lymphocytic Mg would appear to be a better 
indicator of the Mg content of muscle and myocardium and of 
ionized Mg.(70) However, the relation between these last 
evaluations and the Mg pool of the organism remains uncertain.(67) 
Urinary excretion of Mg is highly variable, ranging from                
5 mmol/day-l in the normomagnesimic subject to 0.5 mmol'day-1 
in the deficient subject. Measurement of urinary excretion helps 
separate renal from non-renal causes of hypomagnesemia. In the 
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presence of hypomagnesemia, high urinary excretion suggests that 
increased renal loss is the mechanism of Mg depletion, whereas 
low urinary excretion suggests miscellaneous or gastrointestinal 
causes. Studies of the urinary excretion of Mg after a loading test 
can help diagnose Mg deficiency when magnesemia is normal: the 
subject 'without-deficiency excretes more than 60-70% of Mg 
input,whereas the subject with a deficiency excretes less than 
50%.(70,71) 
Various changes in Mg can occur during the perioperative 
period. Plasma concentrations are decreased after abdominal(72.73) 
or orthopedic surgery.(74) After heart surgery, mean magnesemia is 
reduced(75,76) and the frequency of hypomagnesemia increased 
from 19.2% preoperatively to 71% immediately after surgery 
before dropping slightly to 65.6% 24 hr later.16 For Zuccala et al., 
the depletion of intracellular Mg would appear to be closely 
correlated with reduced serum concentrations. These authors 
found that both concentrations decreased after orthopedic 
surgery.(77) 
 
1.5.2.3. Cellular physiological properties of Mg: 
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1.5.2.3.1. Action on membrane and membrane pumps: 
Mg intervenes in the activation of membrane Ca ATPase 
and Na-K ATPase involved in transmembrane ion exchanges 
during depolarization and repolarization phases. Mg deficiency 
impairs the action of ATPase pumps and leads to a reduction of 
intracellular ATP as well as to increased concentrations of sodium 
and calcium and decreased concentrations of potassium within the 
cell.(78) It would thus appear to act as a stabilizer of cell membrane 
and intracytoplasmic organelles.(79) 
1.5.2.3.2. Action on ion channels: 
Mg is considered to act as a regulator of different ion 
channels. A low intracellular Mg concentration allows potassium 
to leave the cell, thereby altering conduction and cellular 
metabolism.(78,79) Mg also exerts its effects on calcium channels of 
potential-dependent L type in membrane and on those of 
sarcoplasmic reticulum. A competitive antagonist action is 
directed against calcium inflows. By inhibiting the calcium 
activation dependent on the sarcoplasmic channel/ Mg limits the 
outflow of calcium from the sarcoplasmic reticulum, the main site 
of intracellular calcium storage.(79)Thus, Mg is a calcium channel 
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blocker and a modulator of calcium channel activity, which means 
that   a   rise   in   intracellular   calcium   occurs   during 
hypomagnesemia.(66,78) 
1.5.2.3.3. Enzymatic activation: 
Intracellular free Mg is involved in the energy reactions of 
phosphorylation and is necessary for the activation of hundreds of 
enzymatic reactions concerning ATP. Inorganic phosphate and 
ATP within the cell reduce free Mg, whereas the conversion of 
ATP to adenosine diphosphate (ADP) increases it.(69)In fact, Mg 
interacts substrate. Intracellular Mg deficiency is correlated with 
the impaired function of many enzymes utilizing high-energy 
phosphate bonds, as in the case of glucose metabolism.(66) 
1.5.2.4. Clinical effects of Mg: 
• Cardiovascular effects: The action of Mg on calcium channels 
and pumps actually serves as a regulator of transmembrane and 
intracellular flows. In addition, Mg has an indirect effect on 
cardiac muscle cells by inhibiting calcium uptake on the 
troponin C of myocytes and thereby influencing myocardial 
contractility. In a preparation of isolated animal heart, Mg, 
because of its anticalcium properties, caused a dose-dependent 
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negative inotropic effect.(80)   Rasmussen et al. observed a 
moderate positive inotropic effect after infusion of Mg into 
healthy volunteers which could have been related to the 
vascular effect of Mg in reducing systemic arteriaK81) and 
pulmonary artery pressures through a decrease of vascular 
resistance.(79) In vitro studies on isolated aorta, the absence of 
Mg potentiated the vasoconstrictive effect of angiotensin and 
acetylcholine, and hypermagnesemia induced the relaxation of 
smooth muscle.(82) The role of Mg in transmembrane movements 
of calcium and the activation of the adenylate cyclase involved 
in the synthesis of cyclic adenosine monophosphate (AMP; a 
vasodilator) could account in part for this effect. A reduction of 
cyclic AMP in hypomagnesemia induced an increase of vascular 
tone.(83) Mg deficiency may also play a role in the pathogenesis 
of variant angina or coronary spasm(84) and infusion of Mg can 
produce coronary dilatation and suppress acetylcholine-induced 
coronary spasm in  patients  with vasospastic angina.(85) 
In anesthetized dogs, a dose-dependent decrease in heart 
rate and systolic and diastolic arterial pressures was observed after 
the infusion of Mg.(86) In humans, hemodynamic studies have 
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shown a peripheral (predominantly arteriolar) vasodilator 
effect.(87,88) After the rapid infusion of a dose of 3 or 4 g of sulfate 
(MgSO4), a reduction of systolic arterial pressure occurred, in 
relation to decreased systemic vascular resistance. Positive 
inotropic and chronotropic effects compensated for the former by 
increasing the heart index, whereas pulmonary vascular resistance 
remained unchanged. In the study by Vigorito et al., coronary 
vascular resistance decreased as coronary blood flow increased.(89) 
 Disturbances in cellular ionic movements induced by 
dysmagnesemia could affect the excitability of the heart cells of 
nodal tissue responsible for cardiac rhythm disorders.(79)In 
electrocardiographic studies in anesthetized dogs, a dose 
dependent lengthening of the PR and RR intervals was noted, as 
well as a dose-dependent increase of QRS duration, without any 
modification of the QTc interval. A dose-dependent lengthening of 
atrioventricular conduction time was also observed.(86) 
• Muscle and neiiromiiscular transmission: Calcium and Mg have 
opposite effects on muscle. Hypomagnesemia stimulates 
contraction,    whereas   hypocalcemia   induces   relaxation. 
Hypomagnesemia causes rapid, passive release of calcium by the 
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sarcoplasmic reticulum as a result of the opening of calcium 
channels, whereas high concentrations of Mg block this 
process.(89) Neuromuscular transmission is altered by a 
preponderant presynaptic effect as well as a postsynaptic effect. 
Mg acts competitively in blocking the entry of calcium into 
presynaptic endings. Presynaptic release of acetylcholine is 
reduced by high Mg concentrations, thereby altering 
neuromuscular transmission.(67,89) Mg decreases the effects of 
acetylcholine on postsynaptic muscle receptors and has been 
shown to increase the threshold of axonal excitation. 
Hypomagnesemia induces neuromuscular hyperexcitability,(69) 
while hypermagnesemia causes neuromuscular weakness as well 
as a reduction or even an abolition of deep tendon reflexes. 
Excess serum Mg concentrations produce progressive inhibition 
of catecholamine release from adrenergic nerve endings/ adrenal 
medulla and adrenergic postganglionic sympathetic fibres(89,90) 
• Central nervous system: The property of Mg as an antagonist of           
N-methyl-D-aspartate (NMDA) receptors is the basis for studies 
of its adjuvant effect in perioperative analgesia. This calcium 
inhibitory effect causes central arteriolar vasodilation and acts 
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against vasospasm. The inhibition of NMDA receptors and the 
increased production of vasodilator prostaglandins induced by 
Mg could account for the anticonvulsant action of Mg. 
Other clinical effects: 
The postulated mechanisms for the bronchodilator effects of 
Mg includes inhibitory action on smooth muscle contraction, 
histamine release from mast cells and acetylcholine release from 
cholinergic nerve terminals.(67,91) The precise mechanism of action 
for the tocolytic effects(92,93) of Mg sulfate is not clearly defined, but 
may be related to the action of Mg as a calcium blocker in 
inhibiting muscle contractions. 
1.5.2.5. Dysmagnesemia: 
• Hypomagnesemia: Hypomagnesemia, defined as a plasma 
concentration below 0.7 mmol L-l, is considered severe when 
under 0.5 mmol'L-1. This condition is most often associated with 
a true depletion of Mg in the organism, although a Mg deficit 
can exist even when magnesemia is normal. Thus, measurement 
of the urinary excretion of Mg and possibly a loading test can 
help establish the diagnosis.(94)As the bone and intracellular Mg 
reserves of the organism cannot be easily mobilized toward the 
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extracellular sector, a negative Mg balance rapidly leads to 
hypomagnesemia.(6) A deficit was found in 47% of blood 
samples obtained from hospitalized patients with increasing Mg 
thresholds of < 0.6 mmol-L-l, < 0.62 and < 0.74 mmol-L-1 
respectively.(72,80,95,96) The incidence of deficit was much higher in 
patients sampled in surgical and medical intensive care units, 
reaching 61 and 65% to thresholds of 0.75 and 0.7 mmol"L-l 
respectively.(97,98) The high rates for these patients were due to 
an association of several causes of hypomagnesemia. This 
disorder is often overlooked, although it should probably be 
searched for systematically because of its significance for the 
prognosis of patients.(96) In fact, a prospective study of patients 
hospitalized in wards and intensive care units (ICU) showed 
that the death rate was twice as high for the group with 
hypomagnesemia on admission as for the group without a     
deficit.(177) These data were confirmed by Chernow et al. in a 
study of postoperative ICU patients, for whom the death rate 
was 41% vs 13% for patients without hypomagnesemia.(97) Other 
studies after heart surgery showed that patients with 
hypomagnesemia experienced more rhythm disorders. Time on 
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the ventilator was longer(99,100) and morbidity was higher than 
for patients with normal magnesemia.(100) Another study 
showed that a greater than 10% reduction of serum and 
intracellular concentrations was associated with a higher rate of 
postoperative ventricular arrhythmias.(77) As the regulation of 
Mg homeostasis is ensured by the digestive tube or the kidney, 
the main causes of hypomagnesemia are digestive (lack of input 
or absorption, or excessive elimination) or renal (increased 
excretion). 
• Hypermagnesemia: Hypermagnesemia, which is less frequent 
than hypomagnesemia/ was found in 9.3, 5.7 and 3.5% of blood 
samples obtained from hospitalized patients with increasing Mg 
thresholds of > 0.95 mmorL-1, > 0.99 and > 1.07 mmol-L-l  
respectively.(95,96) Moderate hypermagnesemia is frequent in 
patients with chronic renal insufficiency, during 
rhabdomyolysis (due to release of Mg from disintegrating 
muscle) and after excessive use of antacids or laxatives 
containing Mg salts.(101) Severe hypermagnesemia is most often 
observed during the therapeutic administration of Mg sulfate in 
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patients with chronic renal insufficiency or during treatment of 
eclampsia.(102) 
Neuromuscular and cardiovascular manifestations are 
predominant in the clinical symptomatology of hypermagnesemia. 
However, clinical severity is not always correlated with the degree 
of hypermagnesemia.(102) Flushing, nausea and/or vomiting can be 
early signs. Central neurological signs range from somnolence to 
deep coma. Deep tendon reflexes may be reduced or totally lost. 
Breathing may be decreased or even stopped because of paralysis 
of the respiratory muscles. Cardiovascular abnormalities may 
include hypotension because of peripheral vasodilatation, 
conduction disorders (lengthening of the PR and/or QT intervals 
or the QRS complex, and atrioventricular block), bradycardia and 
even cardiac arrest.(71) 
Treatment is based on stopping Mg inputs. An infusion of 
calcium salts, which momentarily antagonizes some Mg effects, 
can be initiated in emergency conditions (2.5-5 mmol in a slow iv  
infusion until disappearance of conduction disorders) when 
neurological   and   cardiovascular   complications   are   life-
threatening.(70'71'89'90) Loop diuretics inhibit renal reabsorption 
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of Mg and induce an increased urinary excretion of Mg, but also of 
calcium, which can cause hypocalcemia and thereby intensify the 
clinical signs of hypermagnesemia. Calcemia needs to be 
monitored,   and   some   authors   recommend   preventive 
administration 'of calcium salts when diuretics are used. For 
patients with renal insufficiency, recourse to dialysis involving a 
Mg-poor fluid is frequent. 
Interactions: 
Potassium supplements, manganese, loop and thiazide 
diuretics, oral contraceptives, estrogen-replacement therapy, 
Cisplatin, cyclosporine, digoxin, or medications that reduce 
stomach acid: You may need extra magnesium. (103,104) 
Antibiotics in the tetracycline family or nitrofurantion 
(Macrodantin): You should separate your magnesium dose from 
doses of these medications by at least 2 hours to avoid absorption 
problems. 
Oral diabetes medications in the sulfonylurea family: Work 
closely with your physician when taking magnesium to avoid 
hypoglycemia. 
What Is the Scientific Evidence for Magnesium? 
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Migraine Headaches: 
A double-blind study found that regular use of magnesium 
helps prevent migraine headaches. In this 12-week trial/105) 
people with recurrent migraines were given either 600 mg of 
magnesium daily or placebo.(106) By the last 3 weeks of the study, 
the treated group's migraines had been reduced by 41.6%, 
compared to a reduction of 15.8% in the placebo group. The only 
side effects observed were diarrhea (in about one-fifth of the 
participants) and, less often, digestive irritation. 
Similar results have been seen in other smaller double-blind 
studies.(107,108) One study found no benefit,(109) but it has been 
criticized on many significant points, including using an 
excessively strict definition of what constituted benefit. (110) 
Noise-related hearing loss: 
One double-blind, placebo-controlled study on 300 military 
recruits suggests that 167 mg of magnesium daily can prevent 
hearing loss due to exposure to high-volume noise.(111) 
Kidney stones: 
Magnesium inhibits the growth of calcium oxalate stones in 
the test tube 60 and decreases stone formation in rats.(112) However, 
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human studies have had mixed results. In one 2-year open study, 
56 people taking magnesium hydroxide had fewer recurrences of 
kidney stones than 34 people not given magnesium, in contrast, a 
double-blind (and, hence, more reliable) study of 124 people found 
that magnesium hydroxide was essentially no more effective than 
placebo.(113) 
Hypertension: 
Magnesium works with calcium and potassium to regulate 
blood pressure. Several studies suggest that magnesium 
supplements can reduce blood pressure in people with 
hypertension.(114,115) although some have not. 
 
Angina: 
In a double-blind, placebo-controlled trial of 187 people 
with angina, 6 months' treatment with magnesium at a dose of 
730mg daily improved exercise tolerance and enhanced overall 
quality of life.(97) Benefits were also seen in a similar, smaller  
double-blind trial.(116) 
Dysmenorrhea: 
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A 6-month, double-blind, placebo-controlled study of 50 
women with menstrual pain found that treatment with 
magnesium significantly improved symptoms.(117) The researchers 
reported evidence of reduced levels of prostaglandin F2 alpha, a 
hormone-like substance involved in pain and inflammation. 
Similarly positive results were seen in a double-blind, 
placebo-controlled study of 21 women.(118) 
Premenstrual symptoms: 
A double-blind/ placebo-controlled study of 32 women 
found that magnesium taken from day 15 of the menstrual cycle to 
the onset of menstrual flow could significantly improve 
premenstrual mood changes.(119) 
In addition, one small double-blind study (20 participants) 
found that magnesium supplementation can help prevent 
menstrual migraines.(120) 
Preliminary evidence suggests that the combination of 
magnesium and vitamin B6 might be more effective than either 
treatment alone.(121) 
Pregnancy-induced leg cramps: 
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Pregnant women frequently experience painful leg 
cramping. One double-blind trial of 73 pregnant women found 
that 3 weeks of magnesium supplements significantly reduced leg 
cramps as compared to placebo.(122) 
One study found that magnesium supplements might be 
helpful for people with mitral valve prolapse who also have low 
levels of magnesium in the blood.(123) 
There is some evidence that magnesium may decrease the 
atherosclerosis risk caused by hydrogenated oils, margarine-like 
fats found in many "junk" foods.(124) 
Studies on magnesium supplements for improving sports 
performance have returned contradictory results.(125,126) 
Magnesium supplements do not appear to be very helpful, 
if at all, for preventing preeclampsia.(127,128,129,130) (Magnesium, 
taken by injection rather than orally, however, is probably helpful 
for treating preeclampsia.(131,111,112) 
Magnesium is sometimes said to decrease symptoms of 
restless legs syndrome, but the evidence that its work consists 
solely of open trials without a placebo group, and such studies are 
not trustworthy(132,133) Magnesium has also been suggested as a 
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treatment for Alzheimer's disease, attention deficit disorder, 
fatigue,   fibromyalgia,   low   HDL-cholesterol,   osteoporosis, 
periodontal disease, rheumatoid arthritis, and stroke. However, no 
reliable evidence exists that it is effective for any of these 
conditions. 
Magnesium is sometimes suggested for stabilizing the heart 
after a heart attack, but one study actually found that use of 
magnesium slightly increased risk of sudden death, repeat heart 
attack, or need for bypass surgery in the year following the initial 
heart attack.(134) 
Despite some early enthusiasm, combination therapy with 
vitamin B6 and magnesium has not been found helpful in 
autism.(105,135,136) 
Although magnesium is sometimes mentioned as a 
treatment to help keep the heart beating normally, a 6-month, 
double-blind trial of 170 people did not find it effective for 
preventing atrial fibrillation.(137) However, a small double-blind, 
placebo-controlled trial found that magnesium supplements 
reduced episodes of arrythmia in individuals with congestive 
heart failure.(138) One possible explanation: people with congestive 
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heart failure often take drugs (loop diuretics) that deplete 
magnesium. The combination of magnesium deficiency with 
digoxin may cause arrhythmias.(139,140,141) Thus, it is possible that 
the benefits seen here were caused by correction of that depletion. 
One double-blind, placebo-controlled study failed to find 
magnesium helpful in glaucoma.(142) 
There is no real evidence that oral magnesium helps 
asthma, and even some evidence that it does not help.(143) 
 
Who may need extra magnesium? 
Magnesium supplementation may be indicated when a 
specific health problem or condition causes an excessive loss of 
magnesium or limits magnesium absorption.(63,144,145,146) 
Some medicines may result in magnesium deficiency, 
including certain diuretics, antibiotics, and medications used to 
treat cancer (anti-neoplastic medication).(147,148,149) Examples of 
these medications are: 
• Diuretics: Lasix, Bumex, Edecrin, and hydrochlorothiazide. 
• Antibiotics: Gentamicin, Amphotericin, and Cyclosporin. 
•  Anti-neoplastic medication: Cisplatin. 
 36
Individuals with poorly-controlled diabetes may benefit 
from magnesium supplements because of increased magnesium 
loss in urine associated with hyperglycemia.(150) 
Magnesium supplementation may be indicated for persons 
with alcoholism. Low blood levels of magnesium occur in 30% to 
60% of alcoholics, and in nearly 90% of patients experiencing 
alcohol withdrawal.(103,104) Anyone who substitutes alcohol for food 
will usually have significantly lower magnesium intakes. 
Individuals with chronic malabsorptive problems such as 
Crohn's disease, gluten sensitive enteropathy, regional enteritis, 
and intestinal surgery may lose magnesium through diarrhea and 
fat malabsorption.(151)Individuals with these conditions may need 
supplemental magnesium. Individuals with chronically low blood 
levels of potassium and calcium may have an underlying problem 
with magnesium deficiency. Magnesium supplements may help 
correct the potassium and calcium deficiencies.(148) Older adults are 
at increased risk for magnesium deficiency. The 1999-2000 and 
1998-94. National Health and Nutrition Examination Surveys 
suggest that older adults have lower dietary intakes of magnesium 
than younger adults.(152,153) In addition, magnesium absorption 
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decreases and renal excretion of magnesium increases in older 
adults.(141) Seniors are also more likely to be taking drugs that 
interact with magnesium. This combination of factors places older 
adults at risk for magnesium deficiency.(64) It is very important for 
older adults to consume recommended amounts of dietary 
magnesium. 
 
 
Magnesium and asthma: 
Several mechanisms have been proposed to explain the 
potential beneficial effect of magnesium in asthma, in vitro 
magnesium causes relaxation of bronchial smooth muscle.(154) This 
may occur by the modulation of the movement of calcium ion, 
both  within the cells and through transmembrane calcium 
channels.(155)In addition, magnesium decreases the amount of 
neurotransmitter release of motor nerve terminals, diminishes the 
depolarizing actions of acetylcholine at the neuromuscular end 
plate, and depresses excitability of smooth muscle membranes(156) 
decrease of acetylcholine at nerve terminals, and of sedative 
action, in addition to inhibition of release of histamine and to 
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direct in inhibition of musculature contraction.(154) By this action it 
decrease the airway resistance, increases forced expiratory volume 
and forced vital capacity and decrease dysnea. The use of 
magnesium for treatment of A. A was first reported in 1936 by 
Uruguayan physicians(155) also in 1983, Haury demonstrated that 
magnesium relaxes smooth muscle and reduces histamine- 
induced broncho-constriction in Quinea pigs.(156) The study by 
Silverman et all suggested that in patients with very severe acute 
asthma, IV magnesium administration improves pulmonary 
function, but it does not prove that IV magnesium should be 
added to the conventional treatment.(157)   
Rowe BH, Camargo CA Jr; Multicenter Airway Research 
Collaboration (MARC) Investigators. Carried out a systemic of 
review of medical literature dealing with the IV magnesium 
sulfate asthma. Most ED physicians accept the efficacy of MgS04 in 
acute asthma. Despite this belief and the ready availability of 
MgS04/ its ED use remains uncommon (2.5% of cases). In both 
practice and theory, emergency physicians appear to 
appropriately restrict its use to patients with severe acute 
asthma.(158) 
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Bloch et al carried out a randomizes double-blind placebo-
controlled study, patients with acute asthma were treated with 
inhaled beta-agonists at regular intervals and intravenous (IV) 
steroids. At 30 min after entry, patients received either 2 g IV 
MgSO4 or IV placebo, and found that Intravenous MgSO4 
decreased admission rate and improved FEV1 in patients with 
acute severe asthma but did not cause significant improvement in 
patients with moderate asthma.(159) 
OBJECTIVES 
 
To evaluate the efficacy of early administration of 
intravenous magnesium sulphate (MgSO4) in adult with acute 
severe asthma not responding to conventional therapy. 
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PATIENTS AND METHODS 
Nature of study: 
Interventional single-blind-controlled clinical trial.  
Patients selection: 
Patients selected by using computer randomized program. 
Patients age 18- to 60 years presenting with acute asthma to the 
Emergency Department (ED of two teaching hospital (Elshaab and 
Oumdrman) between June 2005 and January 2006. 
Exclusion criteria: 
- History of congestive heart failure. 
- Diabetes Mellitus. 
- Angina. 
- Chronic renal insufficiency. 
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- Pregnant women. 
- Hypertension. 
Intervention: 
Conventional therapy 
(Nebulized Salbutamol + IV Hydrocortisone ? 30min) 
 
No magnesium                 I VI magnesium sulfate 2g /20min 
 Eligible patient receive either magnesium sulfate infusion 
of 2g or not. The vital signs, PEFR, oxygen saturation were 
measured before, 30mm, 60min, 90min,120min and 240 minutes 
after the intervention. 
Tools: 
1- Questionnaire: contains the following; 
- History. 
- Full physical examination. 
- Investigations: include: 
- PEFR using Wright peak meter. 
- Oxygen saturation using Pulse Oximeter, 
Statistics: 
Data was analyzed using SPSS computer program. 
Researching Team: 
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- The author 
Ethical consideration: 
- Informed consent from all patients. 
- Informed consent from hospital administration. 
 
3. RESULTS 
Fifty patients were originally enrolled into the study, all 
were included into the statistical analysis and all were classified as 
severe asthmatics based on their initial PEFR/ clinical scenario. 
The study included 50 individuals 55% were female. 
Number of patients who did not receive magnesium were 25. Age 
ranged (18-60 years). Males were 11 and females were 14. 
Number of cases = 25. Age ranged (18 - 60 yr)/ with the same male 
:  
female distribution. 
1. Conclusion of descriptive statistics in asthmatics under study 
(Table 1).  
  Cough: present in all asthmatics under study (50/50) (100%). 
2.  Shortness of breath: present in all asthmatics under study 
50/50%). 
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3.  Wheeze: present in most asthmatics under study 47/50(94%)                
(3 patients in magnesium group presented with silent chest with 
progression to mild wheezes following magnesium therapy and 
remained static until 240 min. 
4.  No one is in exclusion criteria (Fever, Cyanosis, Cardiovascular 
disease, DM, renal insufficiency, pneumonia (Currently), 
pregnancy, chronic liver disease, unconscious) 0/50 (0%). 
5.  All asthmatics admitted to hospital use accessory muscles 
100%). 
6.  Respiratory rate breath >25 is founded in all asthmatics under 
study who came to hospital. 
7.  Most patients and those not receiving magnesium their heart 
beats are above 110 bpm (98%). 
8.  Pulsus paradoxus found in 24% of asthmatic under study. 
9.  Only 2% of asthmatics under study came to hospital, presented 
with chest deformity. 
10.  The commonest type of wheeze was expiratory type (68%) of 
all asthmatics admitted to hospital, followed biphasic 28% and 
then silent 6%. 
11. All asthmatics presented with PEFR  < 300 L/min. 
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12.  SaO2 % predominantly ranged between (85-90) in 94% of all 
asthmatics, followed by SaO2 >90 in 4%, and followed by SaO2% 
<85 in 2%. 
Testing Differences between Magnesium group and Control 
for different signs: 
1. Respiratory rate breath: 
From Graph 1: we can see that significant difference begins 
after 30 minutes (p. value 0.02) and continue up to 240 minutes 
with significant difference (p. value 0.000). 
2. Heart rate: 
From Graph 2: we can see significant difference begins 30 
minutes with p value 0.002,continue significant till 240 
minutes/Mg may be having effect on that, but not less 90 
beats/minute. 
3. Blood pressure: 
All asthmatics came to hospital are in normal blood 
pressure and as seen in graph Mg may has some effect of 
irregularity for Systolic BP but within normal range .the Diastolic 
BP showed the same normality in all asthmatics (Graphs 3 & 4). 
4. Pulsus Paradoxus: 
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The difference begins on 90 minutes P value 0.009, with 
complete absence of pulsus paradoxus eases in patient group, 
which may mean the Mg may have effect reducing this group 
(Table 2). 
5. Use of accessory muscles: 
The difference begins on 90 minutes P value < 0.005, with 
complete absence of using accessory muscles in patient group have 
effect in this group (Table 3). 
6. Wheeze regression: 
The difference begins on 30 minutes P value 0.003, but clear 
significant difference appears in 90 minutes with p value 0.000, 
with dramatic regression at through time in this group compared 
to Control (Table 4) . 
7. PEFR in males: 
The difference begins on 60 minutes P value 0.032 in Mg 
intervened group compared to Control (Table 5). 
8. PEFR in Females: 
As we see in graph the development going gradually but 
significant difference is in 240 minutes P value 0.005 in Mg 
intervened group compared to control (Graph 6). 
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9. SaO2: 
The difference is clear varied and it is significant at 240 
minutes with P. value 0.04 that means Mg intervention has 
improve Oz saturation status (Graph 7). 
PEFR % predicted in Patients and those not received magnesium: 
Mean PEFR in arrivals is 33.7% predicted, after 240 minutes 
the predicted PEFR is 65.1% predicted for patients given 
magnesium and 48.2% predicted for those not received 
magnesium (95% CI 7.97 and 25.89) with P. value 0.005 (Graph 8, 
Table 5). 
Possible side effect of the drug: 
Throughout the study period there was no any side effects 
of the use of intravenous magnesium sulphate among the study 
population. Also no death and no one intubated among those who 
received magnesium sulphate. 
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Table 1: Distribution of clinical symptoms in the study group 
Symptom % 
Cough 50/50 (100%) 
Shortness of breath 50/50 (100%) 
Wheeze 47/50 (94%) 
Fever 0 (0%) 
Cyanosis 0 (0%) 
Cardiovascular disease 0 (0%) 
Diabetes mellitus 0 (0%) 
Renal insufficiency 0 (0%) 
Pneumonia 0 (0%) 
Pregnancy 0 (0%) 
Chronic liver disease 0 (0%) 
Unconscious 0 (0%) 
Use of accessory muscles 50/50 (100%) 
Respiratory rate breath 16-18 0 (0%) 
Respiratory rate breath 18-25 0 (0%) 
Respiratory rate breath > 25 50/50 (100%) 
Heart rate (pbm) up to 90 0 (0.0%) 
Heart rate (pbm) 90-110 1/50 (2%) 
Heart rate (pbm) > 110 49/50 (98%) 
Pulsus paradoxus 12/50 (24%) 
Chest deformity 1/50 (2%) 
Wheeze type (expiratory) 34/50 (68%) 
Wheeze type (Biphasic) 14/50 (28%) 
Wheeze type (silent) 3/50 (6%) 
Cardiovascular examination (normal) 50/50 (100%) 
Cardiovascular examination (abnormal) 0/50 (0%) 
PEFR L/min (1/600 - 400) 0/48 (0%) 
PEFR L/min (400 - 300) 0/48 (0%) 
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PEFR L/min (<300) 50/50 (100%) 
SaO2 % (>90) 2/50 (4%) 
SaO2 % (90 - 85) 47/50 (94%) 
SaO2 % (<85) 1/50 (2%) 
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Table 4: Wheezes regression in patients received MgSO4 and 
those not received MgSO4 from zero time (arrival) through 30, 60, 
90 120, and 240 min. 
 Patient received MgSO4   Patient not received MgSO4    
Wheezes time 00: 
- Severe 
- Moderate 
- Mild 
 
20 
2 
0 
 
24 
1 
0 
Wheezes time 30: 
- Severe 
- Moderate 
- Mild 
 
9 
12 
1 
 
22 
3 
0 
Wheezes time 60: 
- Severe 
- Moderate 
- Mild 
 
1 
20 
1 
 
18 
7 
0 
Wheezes time 90: 
- Severe 
- Moderate 
- Mild 
 
0 
21 
1 
 
8 
16 
1 
Wheezes time 120: 
- Severe 
- Moderate 
- Mild 
 
0 
7 
15 
 
2 
22 
1 
Wheezes time 240: 
- Severe 
- Moderate 
- Mild 
 
0 
0 
22 
 
1 
21 
3 
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Table 5: Mean of peak expiratory flow rate (% predicted) and 
respiratory rate (RR) in MgSO4 and non-magnesium groups 
 
Baseline (the time of zero) 240 min after infusion   
MgSO4 No MgSO4 MgSO4 No MgSO4 
PEFR 33.7 33.5 65.1 48.2 
Respiratory rate 35.23 36.1 24.25 31.32 
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4. DISCUSSION 
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This interventional single-blind controlled clinical trial 
demonstrates that 2 g of IV magnesium sulphate (MgSO4) when 
administered as an adjuvant to standard therapy improves 
pulmonary function in patients presented to Emergency 
Department (ED) with severe asthma. Also from the study there is 
dramatic improvement in clinical scenario (such as respiratory 
rate, heart rate, wheezes, pulsus paradoxus, use of a accessory 
muscles and oxygen saturation status (P. value < 0.005 in all).  
These results supported the use of MgSO4 to improve 
pulmonary function in severe ill asthmatics patients and also 
helped define its limitations. These results also suggested that 
illnesses severity as represented by pulmonary function can be 
important determinant of response to therapeutic interventions 
and this factor should be considered when evaluating new 
treatment regimen. 
Previous controlled studies using adjunct therapy with 
MgSO4 have yielded conflicting conclusions. Skobeloff, et al.(160) 
found that giving 1.2 g of IV MgSO4 to patients in the ED 
significantly improved peak flow and decreased admission rates, 
compared to patients receiving placebo, which is similar to that of 
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our study results. Green and Rothrock(161) using 2 g of MgSO4 
failed to find any difference. However, patients studied by Green 
and Rothrock likely represented a group with less severe disease. 
Also Robert A. Silverman, et al in Multi-center trial demonstrates 
that 2 g of IV MgSO4 administered as an adjuvant to standard 
therapy improves pulmonary function in patients presenting to ED 
with severe asthma which came similar to our results. 
Similarly in a large multicenter study of 248 subjects with 
acute severe asthma, treatment with MgSO4 2 g IV was beneficial 
in the subset of patients who presented with severe airway 
obstruction (forced expiratory volume in 1 second [FEV1] < 25% 
predicted), but not in subjects with less severe airway obstruction. 
(162)However, not all investigators have found benefits in severely 
affected individuals. Porter and colleagues(162) conducted a double-
blinded placebo-controlled trial involving 42 subjects who 
presented to an emergency department with a peak expiratory 
flow rate < 100 L/min (or < 25% predicted). Treatment with 
MgS04 2 g IV in addition to standard therapy was not helpful, and 
in fact, the treated subjects had significantly lower peak expiratory 
flow rate (PEFR) 1 hour after receiving the medication. 
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A number of case reports also indicates MgSO4 is beneficial 
for treating acute severe asthma.(163,164,165,166,167) While results of 
controlled clinical trials evaluating the effect of MgS04 in acutely 
ill ED patients widely differ. When 1.2 g of MgSO4 or placebo was 
administered to 38 patients with moderate to severe airway 
compromise significant improvement occurred in peak flow an 
hospital admission rates.(168) In another study, 2 g of MgSO4 was 
administered to 120 patients with wide range of asthma severity 
and there was no improvement in hospital admission rates or peak 
flow.(169) Again in 48 patients with moderate to severe asthma, no 
significant benefit was noted from 2 g of MgSO4. Also subsequent 
research control trial (33 evaluable people) found no significant 
difference in hospital admissions between intravenous magnesium 
sulphate and placebo. Another subsequent RCT (42 people with 
acute asthma receiving inhaled bronchodilators and IV 
corticosteroids) found that intravenous magnesium sulphate did 
not improve PEFR at 60 minutes compared with placebo (P = 0.04). 
It found no significant difference between treatments in the 
proportion of people admitted to hospital.(7) 
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Different smaller studies use magnesium sulphate as an 
adjuvant to standardized asthma therapy do not demonstrate a 
significant improvement in either PEFR or reduction of hospital 
admission rates' in moderate to severe asthmatics. However, if a 
distinction is made, it is demonstrated that intravenous 
magnesium sulphate does improve both PEFR and reduce hospital 
admission rates in the severe subgroup.(170,171,172) 
Prespecified subgroup analysis of adults with more severe 
airflow obstruction (5 RCTs, sample size not reported; forced 
expiratory volume in 1 second [FEV1] < 30% at presentation, 
failure to respond to initial treatment, or failure to improve 
beyond 60% in FEV1 after 1 hour) found magnesium sulphate 
significantly improved peak expiratory flow rate (PEFR) and 
reduced rates of hospital admission compared with placebo 
(hospital admission rates: OR 0.10, 95% CI 0.04 to 0.27, no 
significant heterogeneity (P > 0.1).(139) 
Taking into consideration potential differences in a 
response to treatment based on illness severity. Block, et al.(173) 
tested 145 patients with varying degrees of air flow obstruction 
 66
was found that only 35 patients with FEV1 <25% predicted had an 
improvement in pulmonary function. 
This randomized, double- blind, controlled study was 
conducted on patient to determine the effect of IV MgSO4 for 
improvement of pulmonary function in patients with acute asthma 
non - responding to routine therapy presenting to the pulmonary 
department. Peak expiratory flow rate (PEFR) was done before 
MgSO4 (25 mg/kg) and normal saline (100 ml) as a baseline criteria 
and after infusion of drugs at 30 min and 3 hr. All patients were 
also given bronchodilators. The main outcome was PEFR. Data 
were analyzed by X2 and t-test and differences between each point 
was considered significant at p< 0.05. The Peak expiratory flow 
rate 3 hrs after baseline increased in MgS04 group in comparison 
with saline group (82.60 5.8 versus 47.8 8.7 P=0.002). Respiratory 
rate of breathing in MgSO4 was also decreased at 30 min and 3 hr 
after baseline. Cyanosis, diaphoresis and using of respiratory 
accessory muscles by patients were decreased in MgSO4 in 
comparison with saline group. According to the results, it is 
suggested that MgSO4 can be as an adjuvant agent for the 
treatment of patients with acute non- responding asthma.(174) 
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Many reports has shown that magnesium sulphate has 
certainly a role as an adjuvant to traditional therapy in asthma and 
asthma-like conditions and has been helpful in the treatment of 
acute exacerbation of asthma.(175) 
This support previous observations that the response to 
MgSO4 is related to initial FEV1, PEFR.  
The mechanism for a beneficial effect of magnesium on 
pulmonary function is not clear. Magnesium is required for a wide 
variety of cellular activities and biological processes, and therefore, 
can potentially exert an effect on any number of pathways, based 
on the present literature, a number of mechanisms can possibly 
explain the immediate improvement noted after administration of 
magnesium in this study points to an acute bronchodilator effect; 
magnesium causes relaxation of bronchial smooth muscle. This 
may occur by modulation of calcium ion movement both within 
the cell and through transmembrane calcium channels.(176) 
Magnesium is also known to decrease the amount of 
neurotrausmitter released at motor nerve terminals, diminishes 
depolarizing action of acetylcholine at neuromuscular end plate 
and depress excitability of smooth-muscle membranes. 
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There is evidence that prostaglandin mediated vascular 
smooth-muscle relaxation is magnesium dependent. Magnesium is 
necessary for steps involving the interaction of Beta-agonist 
receptor complex- G-protein and guanosine triphosphate, leading 
to activation of adenyl cyclase. It has also been reported in vitro 
that magnesium decreases super-oxide production in neutrophilis 
obtained from adult asthmatics; therefore, providing some 
evidence that magnesium has an anti-inflammatory effect. This is a 
possible explanation for the sustained improvement in pulmonary 
function even several hours after magnesium was 
administered.(177) It is not known whether the effect of magnesium 
is primarily due to replacement of an underlying deficiency or 
through a direct pharmacologic effect. Although response to 
magnesium in previous study was independent of baseline serum 
magnesium levels. 
The serum measures may not reflect intracellular 
concentrations or total body stores. Therefore, some patients with 
normal serum levels may have had a deficiency of magnesium. 
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Also, frequent -Beta-agonist therapy, causes acute decreases 
in serum magnesium levels, although the influence on biological 
availability of magnesium is not known. 
Magnesium is relatively inexpensive- readily available and 
easy to administer. Minor side effects can include transient 
flushing, light-headedness, lethargy, nausea, or burning at the IV 
site and transient urticaria. Neither of them occurred in this study. 
Considering the different rout of administrations of 
magnesium sulphate, we found the conclusion of two research 
control trials of nebulised isotonic magnesium sulphate compared 
salbutamol plus 0.9% saline with salbutamol plus isotonic 
magnesium sulphate through a nebuliser and found that 
magnesium sulphate significantly increased PEFR compared with 
0.9% saline (increase in PEFR after 10 minutes: 61% with 
magnesium sulphate 31% with saline; difference 30%, 95% CI 3% 
to 56%; P = 0.03). 
 
Overall this study results were similar to above studies 
results considering the effects of MgS04 on pulmonary function, 
and if there were differences may be in most studied moderate to 
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severe asthmatic patients, but this study targeted only severely ill 
asthmatic patients. Additional studies are needed to better define 
which patients are most likely to benefit from this treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION AND RECOMMENDATIONS 
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• In summary our data indicated that when 2 g of MgSO4 is given 
as an adjuvant to standardized asthma therapy to patients 
presented 'with severe acute asthma, there is significant 
improvement in clinical scenario and pulmonary function. Thus 
these would support routine use of MgSO4 in patients with 
severe acute asthma. 
•  Further larger multicenter studies should support or talk more 
about the effect of MgSO4 on moderate to severe Sudanese 
asthmatic patients. 
• Also should address optimal dose and infusion rates of I.V 
MgSO4. 
•  Finally a large multicenter controlled study should be done 
comparing the effect of nebulised magnesium sulphate versus 
IV magnesium sulphate (nebulised Vs IV MgS04) as an adjunct 
to conventional asthma therapy in patients with severe acute 
asthma in Sudan. 
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University of Khartoum 
Graduate Colleague 
Efficacy of l.V Magnesium Sulfate in Acute Severe asthma 
In Khartoum Teaching Hospitals 
 
1. Name: ........................................................................... 2. Age: ........................................................................... 
2. Sex:                 1 -Male         2- Female 
C/O:  
1. Cough                  1- Yes        2-No 
2. SOB                      1-Yes        2-No 
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3. Wheeze                1-Yes         2-No 
4. Fever                   1- Yes           2-No 
5. Cyanosis             1-Yes        2-No 
History of: 
1. Cardiovascular Dis.   1-Yes         2-No 
2. DM            1-Yes        2-No 
3. Renal insufficiency   1- Yes         2-No 
4. Pneumonia (currently)   1-Yes          2-No       
5. Pregnancy          1- Yes          2-No 
6. Chronic liver Dis.              1- Yes      2-No 
O/E: 
1. Conscious               1-Yes     2-No 
 2. Use of accessory respiratory muscles    1-Yes    2- No 
3. Respiratory Rate Breaths/min 
                                 1-   16-18           2-   18-25            3-   > 25 
4. Heart Rate (b pm) 
1- Up, 90         2- 90-110      3-   >110  
5. Pulsus Paradoxus        1- Yes       2-No 
Chest Deformity    1- Yes        2-No 
Wheeze         1- Expiratory      2- Biphasic    3- Silent chest 
CVS/E          1- Normal       2-Abnormal 
 Investigations 
1. PEFR/min.      
1. 1/600 – 400     2. 400 – 300      3. < 300 
2. SO2            1. >90         2. 90 – 85                3. < 85% 
Intervention: 
All patients received nebulized salbuamol initially every 20 
min, hydrocortisone 200 mg I.V + 2 g of magnesium sulfate 2g in 100 ml 
(N.S 0.9), I.V over 20 min.     
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L/min 
SO2%  Silen
ches
0 19 6 19 6 19 6 19 5 20
30          
60          
90          
120          
240          
          
          
          
          
          
          
 
 
